華潤三九(000999.SZ)中藥產品參附註射液以及生脈注射液進入新型冠狀病毒感染的肺炎診療方案(試行第四版)
格隆匯2月3日丨華潤三九(000999.SZ)公佈,公司股票於2020年1月23日、2月3日連續2個交易日收盤價格漲幅偏離值累計超過20%,根據《深圳證券交易所交易規則》的有關規定,屬於股票交易異常波動。
近期部分傳媒對公司在新型冠狀病毒感染肺炎疫情防控中的工作進行了報道,相關報道未涉及未公開重大信息。為打贏防疫攻堅戰,履行央企社會責任,春節期間,公司緊急部署,迅速調整生產計劃,優先組織防疫品種的生產,保障藥品的供應。公司中藥產品參附註射液以及生脈注射液,進入《新型冠狀病毒感染的肺炎診療方案(試行第四版)》,受到推薦使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.